ribociclib
novartis
['breast', ' ribo', 'ribociclib']
 these results support ribociclib plus endocrine therapy as a new &amp; effective treatment of choice for a broad population of at-risk patients w/ stage ii or iii hr-positive/her2-negative early breast cancer, which is easy to identify in clinical practice, dennis j. slamon md phd 
Nonprofit organization dedicated to providing the most reliable, complete, and up-to-date information about breast cancer and breast health.